237 related articles for article (PubMed ID: 27607173)
1. 68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer.
Sachpekidis C; Kopka K; Eder M; Hadaschik BA; Freitag MT; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2016 Nov; 41(11):e473-e479. PubMed ID: 27607173
[TBL] [Abstract][Full Text] [Related]
2. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Early dynamic imaging in
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; Warwitz B; Scarpa L; Roig LG; Kendler D; von Guggenberg E; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):765-775. PubMed ID: 27900519
[TBL] [Abstract][Full Text] [Related]
5.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
6.
Sachpekidis C; Bäumer P; Kopka K; Hadaschik BA; Hohenfellner M; Kopp-Schneider A; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):904-912. PubMed ID: 29362859
[TBL] [Abstract][Full Text] [Related]
7. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Uprimny C; Kroiss AS; Fritz J; Decristoforo C; Kendler D; von Guggenberg E; Nilica B; Maffey-Steffan J; di Santo G; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
[TBL] [Abstract][Full Text] [Related]
8. Combined whole-body dynamic and static PET/CT with low-dose [
Sachpekidis C; Pan L; Groezinger M; Strauss DS; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2137-2150. PubMed ID: 38286936
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract][Full Text] [Related]
10. Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma.
Sahlmann CO; Meller B; Bouter C; Ritter CO; Ströbel P; Lotz J; Trojan L; Meller J; Hijazi S
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):898-905. PubMed ID: 26563122
[TBL] [Abstract][Full Text] [Related]
11.
Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
[TBL] [Abstract][Full Text] [Related]
12. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
13. Comparison of [
Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
[TBL] [Abstract][Full Text] [Related]
14. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L
Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090
[TBL] [Abstract][Full Text] [Related]
15. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
[TBL] [Abstract][Full Text] [Related]
16. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
[TBL] [Abstract][Full Text] [Related]
17. 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer.
Fendler WP; Schmidt DF; Wenter V; Thierfelder KM; Zach C; Stief C; Bartenstein P; Kirchner T; Gildehaus FJ; Gratzke C; Faber C
J Nucl Med; 2016 Nov; 57(11):1720-1725. PubMed ID: 27261520
[TBL] [Abstract][Full Text] [Related]
18. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
[TBL] [Abstract][Full Text] [Related]
19. Optimal time-point for
Beheshti M; Paymani Z; Brilhante J; Geinitz H; Gehring D; Leopoldseder T; Wouters L; Pirich C; Loidl W; Langsteger W
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1188-1196. PubMed ID: 29476228
[TBL] [Abstract][Full Text] [Related]
20. Comparison of parametric imaging and SUV imaging with [
Chen R; Ng YL; Yang X; Zhu Y; Li L; Zhao H; Zhou Y; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):568-580. PubMed ID: 37792025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]